5-MAPB

5-MAPB
Clinical data
Other names	5-(N-Methyl-2-aminopropyl)benzofuran
Routes of; administration	Oral
Drug class	Serotonin–norepinephrine–dopamine releasing agent; Serotonin 5-HT1B receptor agonist; Serotonin 5-HT2 receptor agonist
Legal status
Legal status	CA: Schedule I; DE: NpSG (Industrial and scientific use only); UK: Class B; Illegal in China;
Pharmacokinetic data
Duration of action	5–6 hours
Identifiers
	IUPAC name 1-(Benzofuran-5-yl)-N-methylpropan-2-amine;
CAS Number	1354631-77-8;
PubChem CID	102336592;
ChemSpider	32078887;
UNII	XW34GUY2OY;
CompTox Dashboard (EPA)	DTXSID801017189 DTXSID301010102, DTXSID801017189 ;
Chemical and physical data
Formula	C12H15NO
Molar mass	189.25 g/mol (freebase); 225.7 g/mol (HCl salt) g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(NC)CC1=CC(C=CO2)=C2C=C1;
	InChI InChI=1S/C12H15NO/c1-9(13-2)7-10-3-4-12-11(8-10)5-6-14-12/h3-6,8-9,13H,7H2,1-2H3; Key:ZOVRTIPCNFERHY-UHFFFAOYSA-N;

5-MAPB, also known as 5-(N-methyl-2-aminopropyl)benzofuran, is an entactogen and designer drug of the amphetamine family that is similar to MDMA in its structure and effects.

5-MAPB was first encountered as a novel designer drug in 2013 and described in the scientific literature in 2014. It has been patented by Tactogen as an entactogen for potential use as a medicine.